Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) Chewable Tablets and VETMEDIN Solution ...
Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...
A strategic partnership with CommonSpirit Health aims to increase adherence to evidence-based guidelines (EBGs), improving screening and diagnosis of cardio-kidney-metabolic (CKM) diseases -- The ...
-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Scott Drutman Incoming Chief Medical Officer of Enara Bio Boehringer Ingelheim exercises option to license additional Dark ...
Boehringer Ingelheim announced an agreement with Quallent Pharmaceuticals, a private label pharmaceutical distributor, to help expand patient access to citrate-free adalimumab-adbm, Boehringer’s ...
Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...
Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...
INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech ...
Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback